Manufacturing Cellares and TScan to assess automated manufacturing of TSC-101 therapy Pharmaceutical TechnologyCellares and TScan Therapeutics have entered a deal to assess automated manufacturing for TScan's TSC-101 therapy in AML and MDS patients.OncologyRead full story pharminent June 4, 2026 (Last updated: June 4, 2026) Pharmaceutical Technology Cellares and TScan Therapeutics have entered a deal to assess automated manufacturing for TScan’s TSC-101 therapy in AML and MDS patients. Oncology Read full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: A Spanish biotech banks $87M to make differentiated ADCsNext: Eli Lilly continues genetic medicine push with $1.9bn Ascidian partnership Related Stories Manufacturing J&J Streamlines Pharma Supply Chain Amid $55B US Manufacturing Push pharminent July 15, 2026 Manufacturing Cellares and Sonoma partner to automate cell therapy manufacturing pharminent July 14, 2026 Manufacturing “Hub-and-spoke” drug manufacturing set to benefit from new FDA rule pharminent July 13, 2026
